secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000805928-24-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen reports Q4 2023 revenue $42.9M (+18.7% YoY); 2024 revenue guidance $177-181M
--------------------------------------------------------------------------------

- Q4 net loss $3.9M ($0.09/share) vs $5.4M loss in Q4 2022; adjusted EBITDA turned positive at $0.6M.
- Full-year 2023 revenue $159.0M (+14.7% YoY); net loss $21.7M vs $28.9M in 2022.
- Gross margin declined: Q4 78.7% vs 83.0%; FY 80.4% vs 82.6%. Guidance expects 76-79% for 2024.
- FDA pre-BLA agreement for Avance nerve graft; rolling submission in Q3 2024, potential approval mid-2025.
- Avive+ Soft Tissue Matrix launch planned in Q2 2024; core accounts grew 13.3% to 376.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/0000805928-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000025/axgn-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000805928-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer